Vaccitech plc Stock News

OXFORD, United Kingdom, June 21, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics

While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, the market presence of the surprise production cuts

OXFORD, United Kingdom, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics

OXFORD, United Kingdom, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics

Vaccitech PLC Sponsored ADR (VACC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

OXFORD, United Kingdom, July 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutic

Gainers Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) shares surged 69.5% to $2.1199 after the company announced it has developed a non-invasive blood sensor designated to alert real-time chang

VTP-300 作為單藥治療和與單次給藥的低劑量納武利單抗聯合使用時，沒有出現與治療相關的嚴重不良事件和罕見的短暫性轉氨酶升高。

VTP-300无论是作为一种单药，或是与一种低剂量纳武单药给药联合使用，均未出现与治疗相关的严重不良事件和罕见的短暂性转氨酶升高现象。

VTP-300을 단일요법으로, 또는 저용량의 니볼루맙을 1회 함께 투여했을 때, 치료를 요하는 위중한 부작용은 나타나지 않았으며, 낮은 확률로 발현된 아미

Vaccitech plc (NASDAQ: VACC) announced an update to the interim analysis of safety and efficacy data from the HBV002 study evaluating ChAdOx1-HBV and MVA-HBV vaccines (VTP-300) in chronic HBV pat

VTP-300 as a monotherapy and in combination with a single administration of low-dose nivolumab was administered, with no treatment-related serious adverse events and infrequent transient transaminitis

OXFORD, United Kingdom, June 06, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutic

OXFORD, United Kingdom, June 06, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics

Trial will evaluate AB-729, an RNAi therapy in combination with VTP-300, an immunotherapeutic, and NA therapy Trial will evaluate AB-729, an RNAi therapy in combination with VTP-300, an immunotherapeu